Higher Hemoglobin Trigger May Aid Brain Injury Recovery, Meta-Analysis Finds

For decades, intensive care physicians have faced an uncomfortable dilemma at the bedside of patients with acute brain injury: how low can the blood hemoglobin level fall before a red blood cell transfusion becomes necessary? Transfusing too liberally exposes patients to the risks of donor blood, fluid overload, and immune complications, while waiting too long risks starving an injured brain of the oxygen it desperately needs. A new Bayesian network meta-analysis published in Neurocritical Care offers the most comprehensive ranking yet of four commonly used transfusion thresholds, and its conclusion is striking: a trigger of 9 grams per deciliter, considerably higher than the restrictive thresholds favored in general critical care, ranked best for functional recovery among patients with acute brain injury.

The study, led by Xing Wang and colleagues at West China Hospital of Sichuan University, systematically searched PubMed, Embase, MEDLINE, and the Cochrane Library for randomized controlled trials comparing red blood cell transfusion thresholds in patients with acute brain injury, a category encompassing traumatic brain injury, aneurysmal subarachnoid hemorrhage, and spontaneous intracerebral hemorrhage. The final analysis pooled six randomized controlled trials comprising 2,599 patients, evaluating four distinct hemoglobin thresholds of 7, 8, 9, and 10 grams per deciliter. Rather than simply splitting trials into liberal versus restrictive camps, the researchers used Bayesian network meta-analysis, a statistical framework that combines direct comparisons within trials with indirect comparisons across the network of treatments, allowing all four thresholds to be ranked against one another even where head-to-head data were sparse.

The headline result concerns functional outcome, the measure that matters most to patients and families after brain injury. Compared with a transfusion threshold of 7 grams per deciliter, the most restrictive strategy evaluated, a threshold of 9 grams per deciliter was associated with a lower risk of unfavorable functional outcome, with a risk ratio of 0.86 and a 95 percent credible interval of 0.78 to 0.94. Crucially, this estimate rested on direct evidence from two randomized trials, lending it considerable weight. When compared against a threshold of 8 grams per deciliter, the estimate again favored the 9 gram trigger, with a risk ratio of 0.79, but the credible interval of 0.63 to 1.00 just touched the boundary of statistical significance, and this comparison relied on indirect evidence chains rather than direct head-to-head trials.

On the question of mortality, the picture was more equivocal. No threshold demonstrated a clear survival advantage over the others, and the analysis found no significant differences in adverse events, including infectious complications and thromboembolic events, across the evaluated strategies. This safety profile matters, because one of the principal theoretical objections to liberal transfusion in the critically ill has been the fear that additional transfusions would drive infections, venous thrombosis, or transfusion-related circulatory overload. In this analysis, the 9 gram per deciliter threshold achieved its functional benefit without a measurable penalty in these safety domains.

To quantify the relative standing of each strategy, the researchers employed the surface under the cumulative ranking curve, or SUCRA, a metric that converts the network of comparisons into a single probability-based ranking for each treatment. The 9 gram per deciliter threshold ranked highest on SUCRA values for both mortality and neurological outcomes, emerging as the most favorable option among those evaluated. The 7 gram per deciliter threshold, long the default restrictive trigger in general intensive care based on landmark trials in non-neurological patients, fared comparatively poorly for neurological recovery, even though it remains widely endorsed for other critically ill populations.

The biological rationale for a higher trigger in brain injury is grounded in cerebral physiology. The injured brain is exquisitely vulnerable to secondary insults, and anemia reduces arterial oxygen content at precisely the moment when damaged tissue may be operating near the threshold of hypoxic injury. In regions of compromised autoregulation, the normal compensatory response of increasing cerebral blood flow may be blunted, meaning that a falling hemoglobin concentration translates more directly into tissue hypoxia. Experimental and observational work has linked anemia after traumatic brain injury and subarachnoid hemorrhage to worse neurological outcomes, and cohort studies such as CENTER-TBI and the SYNAPSE-ICU study have documented how frequently anemia occurs and how variable transfusion practice remains across intensive care units worldwide.

The authors also probed the sources of inconsistency among prior studies through meta-regression, a technique that examines whether trial-level characteristics modify treatment effects. Their analysis suggested that the baseline hemoglobin level of enrolled patients may represent a potential source of heterogeneity in how liberal transfusion strategies influence functional outcomes. In practical terms, patients who arrive anemic may respond differently to a higher transfusion trigger than those who only drift downward gradually, a finding that could help explain why earlier syntheses of liberal versus restrictive strategies produced conflicting conclusions.

The new analysis arrives amid a burst of high-profile trials that have reshaped, but not settled, this debate. The 2024 HEME trial published in the New England Journal of Medicine found no clear mortality or functional difference between liberal and restrictive strategies in traumatic brain injury, while a subsequent 2025 trial in aneurysmal subarachnoid hemorrhage likewise reported nuanced results. Multiple systematic reviews and meta-analyses published between 2024 and 2026 have wrestled with these data, some favoring liberal approaches for neurological recovery and others finding no effect. What distinguishes the current work is its network design: instead of forcing every trial into a binary liberal-versus-restrictive comparison, it treats each numeric threshold as a distinct treatment and ranks them simultaneously, a method aligned with PRISMA extension reporting standards for network meta-analyses and with GRADE and Cochrane risk-of-bias frameworks for evidence appraisal.

Nevertheless, the authors and the broader neurocritical care community caution against premature certainty. Six trials and 2,599 patients represent a modest evidence base for a question of this magnitude, and the thresholds themselves were operationalized differently across trials. The finding that the 9 versus 8 gram comparison lacked statistical significance underscores the limits of indirect estimation, and SUCRA rankings, while useful for decision-making, inherit every uncertainty present in the underlying network. Guidelines from the American Heart Association and American Stroke Association and neurocritical care societies have so far stopped short of mandating a single trigger, and the new analysis is unlikely to change that stance on its own.

Even so, the study represents a meaningful step toward precision in one of neurocritical care’s most persistent controversies. If the 9 gram per deciliter threshold is confirmed in adequately powered, dedicated trials that directly compare intermediate triggers, hundreds of thousands of patients with traumatic brain injury, subarachnoid hemorrhage, and intracerebral hemorrhage could see transfusion decisions guided by evidence rather than by institutional habit. For now, the message for clinicians is nuanced but actionable: in the injured brain, the general intensive care rule of waiting until hemoglobin falls to 7 grams per deciliter may be too conservative, and the intermediate territory around 9 grams per deciliter deserves careful consideration when the goal is protecting neurological recovery rather than merely keeping patients alive.

Subject of Research: Optimal red blood cell transfusion thresholds for patients with acute brain injury

Article Title: Optimal Transfusion Thresholds in Patients with Acute Brain Injury: A Bayesian Network Meta-analysis of Randomized Controlled Trials

Article References: Wang, X., Fu, W., Chen, W., Ma, L., & You, C. (2026). Optimal Transfusion Thresholds in Patients with Acute Brain Injury: A Bayesian Network Meta-analysis of Randomized Controlled Trials. Neurocritical Care. https://doi.org/10.1007/s12028-026-02674-1

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02674-1

Keywords: transfusion thresholds, acute brain injury, hemoglobin, anemia, Bayesian network meta-analysis, randomized controlled trials, traumatic brain injury, subarachnoid hemorrhage, neurocritical care, functional outcome, mortality, intensive care